Corticosteroids have been used in the management of autoimmune blistering diseases
(AIBD) for more than 50 years, and are an essential component in the pharmacologic
management of these conditions. While providing rapid remission and ongoing control of the
symptoms of AIBD, they come with a variety of potentially serious acute and long-term side
effects. The advent of immunomodulating and immunosuppressive therapies has
complemented the use of corticosteroids but have not usurped its pivotal role. The advent of …